Community pharmacists and early skin cancer detection

Australia has one of the world’s highest melanoma burdens, and Queensland records a substantial share of the country’s skin cancers. Strong ultraviolet radiation, year-round outdoor activity and a culture of relaxed sun exposure make early detection especially important. A suspicious lesion that is noticed early is more likely to be assessed promptly and treated successfully. Community pharmacists can support early detection in high-risk populations without replacing a doctor’s diagnosis or a dermatologist’s examination.

Because they are local, accessible and often used by people who may not attend regular primary care, pharmacists are well placed to identify risk, notice concerning changes and direct people towards the right service. Their contribution is strongest when it forms part of a defined pathway involving general practitioners, dermatologists, nurses and community health services. This approach also supports local research translation, service evaluation and improvement in care equity.

Why community pharmacies matter for early detection

A pharmacy is often the easiest health service to reach without an appointment, making it valuable for people living with disability, older adults, outdoor workers and families facing transport or cost barriers. Pharmacists already discuss medicines, vaccinations and chronic disease, so they can naturally include skin health without making the conversation feel unusual. A discreet question about a new or changing spot can reveal a problem that might otherwise remain unnoticed for months.

The need is particularly relevant across Brisbane, the Gold Coast and regional Queensland, where sun exposure differs by season and work but remains substantial. Outdoor agriculture, construction and mining create repeated exposure, while residents of Townsville and the Far North face intense UV and longer journeys to specialist services. In smaller and remote communities, the nearest pharmacy may be the most practical point of contact with health professionals. The collaborative model used by Brisbane Diamantina Health Partners shows how pharmacy, university, research and health-service partnerships can adapt one pathway for different communities.

Spotting risk and suspicious changes

Risk assessment should consider a personal or family history of melanoma, numerous or atypical moles, severe sunburn in childhood, outdoor work, fair skin that burns easily, previous skin cancers and immune suppression. Risk is not a matter of skin colour alone, and Aboriginal and Torres Strait Islander people should receive culturally safe assessment rather than being treated as a low-risk group. Pharmacists can use the ABCDE guide—Asymmetry, Border irregularity, Colour variation, Diameter often greater than six millimetres, and Evolution—but also ask whether a lesion is new, changing, unlike the others, itchy, bleeding or not healing. Raised or scaly lesions require attention even when they lack pigment.

Any visual inspection should be brief, private, consensual and within the pharmacist’s scope, with the person invited to point out concerns rather than subjected to an unexpected examination. Education can reinforce Australia’s familiar sun-protection habits: broad-spectrum SPF 50+ sunscreen, a wide-brimmed hat, sunglasses, shade and protective clothing, with sunscreen reapplied as directed. These habits are especially important for outdoor workers. Public health messaging should also be co-designed through community-led health messaging, ensuring that information reflects local routines, language and trusted relationships rather than arriving as a generic warning.

Building a safe referral pathway

A safe pathway starts with predetermined actions for suspicious findings. A rapidly changing, bleeding or ulcerated lesion needs prompt GP assessment, while a concerning pigmented lesion should not wait for the next routine pharmacy visit. Pharmacists should document the site, approximate size, symptoms and duration, then provide a concise referral with permission for information to be shared. They should not label a lesion as cancer, use unvalidated point-of-care tests or imply that a brief visual check replaces a full skin examination and, where indicated, dermoscopy.

The strongest models close the loop: the pharmacy confirms that a referral was received, reinforces the plan and helps the person rebook if an appointment was missed. Training should cover criteria, communication, privacy and local escalation routes, with regular review of referral completion and equity. Research can also test whether community pharmacies improve earlier presentation; blood-based marker studies may draw on ISEV scientific resources, but laboratory evidence should not be promoted as a ready-to-use diagnostic in pharmacies. Direct evidence that pharmacist-led detection alone reduces mortality remains limited, making careful evaluation essential.

Practical steps for pharmacies and health partners

A consistent program is easier to sustain than a one-off event. Each participating pharmacy should agree on responsibilities, staffing, training, referral destinations and documentation standards before offering the service.

• Build a trained team and define which observations each pharmacist is qualified to make.
• Ask about changing or unusual moles and lesions during suitable private moments, without assuming a person’s risk from appearance.
• Use one agreed escalation checklist and provide a clear urgent pathway to local medical care.
• Maintain referral templates, consent procedures and a secure method for communicating information.
• Stock evidence-based sun-protection advice and products, including Australian-standard broad-spectrum SPF 50+ sunscreen.
• Audit referrals, appointments, patient experience and missed care, then report improvements to partner services.

Follow-up should be offered at the next relevant visit, and barriers should be discussed without blame. A pharmacy that sees a high volume of suspicious lesions but cannot secure timely review should escalate the problem to the local partnership rather than simply recording more referrals. Cancer Council Australia and primary-care teams can provide consistent public education, while local relationships determine which referral route is realistic for each community.

A shared commitment to earlier action

Earlier detection is a shared responsibility, not a task that can sit solely with pharmacists. Community pharmacies can provide repeated, trusted contact; GPs can assess the whole skin and organise investigations; dermatologists can confirm diagnoses and treat; and Aboriginal Community Controlled Health Services and other local services can provide culturally safe care for communities with barriers to mainstream services. In Queensland, coordinating these roles is essential because distances, workforce distribution and social conditions shape whether a referral becomes timely treatment.

The immediate action is to convene local pharmacists, primary-care clinicians, specialist services and community representatives to launch a measurable pathway in one participating area. The pilot should specify who is trained, how urgent lesions are escalated, when people are contacted again and which outcomes will be reported. Establish the partnership, train the team and begin earlier skin cancer detection together.